New artificial intelligence model can predict bowel cancer severity: Study

The noninvasive method was described in a study, published in the journal Science Translational Medicine, and adds to advances in technologies that analyse circulating tumour DNA (ctDNA)

Chip-based cancer test may replace painful bone biopsy
Press Trust of India Beijing
2 min read Last Updated : Jan 02 2020 | 8:06 PM IST

Researchers have developed a new artificial intelligence (AI) system which can help identify patients with bowel cancer, an advance that may help predict the severity of the malignant disease.

The noninvasive method was described in a study, published in the journal Science Translational Medicine, and adds to advances in technologies that analyse circulating tumour DNA (ctDNA).

According to the researchers, including those from Huazhong University of Science and Technology in China, the new method can help spot bowel cancers in at-risk patients at earlier stages.

They said the cancer type is most treatable if it is detected before they have spread to other sites in the body.

Colonoscopy is regarded as the "gold standard" for diagnosis, but the scientists said the procedure is uncomfortable and invasive and can lead to complications, leaving patients less willing to undergo screening.

The scientists leveraged AI techniques, where systems self-learned to perform specific tasks without explicit instructions, to develop a less invasive diagnostic method that can detect bowel cancer in at-risk patients.

According to the study, the technology works by screening for methylation markers, which are chemical modifications to DNA which are frequently found in tumours.

The researchers first created a diagnostic model based on nine methylation markers associated with bowel cancer, which they identified by studying samples of the blood component plasma from 801 patients with the malignant disease, as well as 1,021 controls.

This model accurately distinguished patients from healthy individuals with a sensitivity of 87.5 per cent, and outperformed a clinically available blood test named CEA.

With longer follow-up periods, the researchers said the machine learning model needs to be further assessed for reliability in detecting tumour in patients.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :cancer

First Published: Jan 02 2020 | 4:00 PM IST

Next Story